Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Outcomes of Treatment-Resistant Depression in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 60 and older~* Current Major Depressive Disorder (MDD)~* Failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length~* Patient Health Questionnaire-9 (PHQ-9) score of 10 or higher~Exclusion Criteria:~* Inability to provide informed consent~* Dementia~* Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms~* High risk for suicide and unable to be managed safely in the clinical trial~* Contraindication to proposed study medications, as determined by study physician including history of intolerance or non-response to proposed medications.~* Non-correctable, clinically significant sensory impairment interfering with participation~* Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management.~* Moderate to severe substance or alcohol use disorder

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aripiprazole Augmentation (Type: EXPERIMENTAL): Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.
- Bupropion Augmentation (Type: EXPERIMENTAL): Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.
- Switch to Bupropion (Type: EXPERIMENTAL): Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
- Lithium Augmentation (Type: EXPERIMENTAL): Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
- Switch to Nortriptyline (Type: EXPERIMENTAL): Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).